Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 356 entries
Sorted by: Best Match Show Resources per page
Risperidone, quetiapine, and olanzapine adjunctive treatments in major depression with psychotic features: a comparative study.

Neuropsychiatric disease and treatment

Gabriel A.
PMID: 23596349
Neuropsychiatr Dis Treat. 2013;9:485-92. doi: 10.2147/NDT.S42745. Epub 2013 Apr 12.

OBJECTIVES: The purpose of this study was to compare the effectiveness of novel antipsychotics in the treatment of psychotic depression.METHOD: Consecutive patients who were admitted (n = 51) with a confirmed diagnosis of major depression with psychotic features (delusions...

Cite
Gabriel A. Risperidone, quetiapine, and olanzapine adjunctive treatments in major depression with psychotic features: a comparative study. Neuropsychiatr Dis Treat. 2013;9:485-92doi: 10.2147/NDT.S42745.
Gabriel, A. (2013). Risperidone, quetiapine, and olanzapine adjunctive treatments in major depression with psychotic features: a comparative study. Neuropsychiatric disease and treatment, 9485-92. https://doi.org/10.2147/NDT.S42745
Gabriel, A. "Risperidone, quetiapine, and olanzapine adjunctive treatments in major depression with psychotic features: a comparative study." Neuropsychiatric disease and treatment vol. 9 (2013): 485-92. doi: https://doi.org/10.2147/NDT.S42745
Gabriel A. Risperidone, quetiapine, and olanzapine adjunctive treatments in major depression with psychotic features: a comparative study. Neuropsychiatr Dis Treat. 2013;9:485-92. doi: 10.2147/NDT.S42745. Epub 2013 Apr 12. PMID: 23596349; PMCID: PMC3627471.
Copy Download .nbib Format: NLM
Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies.

Neuropsychiatric disease and treatment

Gopal S, Liu Y, Alphs L, Savitz A, Nuamah I, Hough D.
PMID: 24092977
Neuropsychiatr Dis Treat. 2013;9:1381-92. doi: 10.2147/NDT.S49944. Epub 2013 Sep 20.

BACKGROUND: The purpose of this study was to compare incidence rates and time course of extrapyramidal symptom (EPS)-related treatment-emergent adverse events (TEAEs) between oral and long-acting injectable (LAI) paliperidone.METHODS: The analysis included pooled data (safety analysis set, 2,256 antipsychotic-treated...

Cite
Gopal S, Liu Y, Alphs L, et al. Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies. Neuropsychiatr Dis Treat. 2013;9:1381-92doi: 10.2147/NDT.S49944.
Gopal, S., Liu, Y., Alphs, L., Savitz, A., Nuamah, I., & Hough, D. (2013). Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies. Neuropsychiatric disease and treatment, 91381-92. https://doi.org/10.2147/NDT.S49944
Gopal, Srihari, et al. "Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies." Neuropsychiatric disease and treatment vol. 9 (2013): 1381-92. doi: https://doi.org/10.2147/NDT.S49944
Gopal S, Liu Y, Alphs L, Savitz A, Nuamah I, Hough D. Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies. Neuropsychiatr Dis Treat. 2013;9:1381-92. doi: 10.2147/NDT.S49944. Epub 2013 Sep 20. PMID: 24092977; PMCID: PMC3788701.
Copy Download .nbib Format: NLM
Pharmacogenetics of risperidone response and induced side effects.

Personalized medicine

Correia C, Vicente AM.
PMID: 29788673
Per Med. 2007 Aug;4(3):271-293. doi: 10.2217/17410541.4.3.271.

Risperidone is an atypical antipsychotic that has been effectively used to treat several psychiatric diseases. Atypical antipsychotics present some advantages over conventional antipsychotics, primarily because they offer effective treatment alternatives that are relatively free of extrapyramidal symptoms. However, as...

Cite
Correia C, Vicente AM. Pharmacogenetics of risperidone response and induced side effects. Per Med. 2007;4(3):271-293doi: 10.2217/17410541.4.3.271.
Correia, C., & Vicente, A. M. (2007). Pharmacogenetics of risperidone response and induced side effects. Personalized medicine, 4(3), 271-293. https://doi.org/10.2217/17410541.4.3.271
Correia, Catarina, and Vicente, Astrid M. "Pharmacogenetics of risperidone response and induced side effects." Personalized medicine vol. 4,3 (2007): 271-293. doi: https://doi.org/10.2217/17410541.4.3.271
Correia C, Vicente AM. Pharmacogenetics of risperidone response and induced side effects. Per Med. 2007 Aug;4(3):271-293. doi: 10.2217/17410541.4.3.271. PMID: 29788673.
Copy Download .nbib Format: NLM
Reduction of Severity of Recurrent Psychotic Episode by Sustained Treatment with Aripiprazole in a Schizophrenic Patient with Dopamine Supersensitivity: A Case Report.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology

Tadokoro S, Nonomura N, Kanahara N, Hashimoto K, Iyo M.
PMID: 28138118
Clin Psychopharmacol Neurosci. 2017 Feb 28;15(1):79-81. doi: 10.9758/cpn.2017.15.1.79.

Dopamine supersensitivity psychosis (DSP) is a type of acute exacerbation of recurrent psychosis caused by long-term treatment with antipsychotics in schizophrenic patients. Although DSP is exceedingly troublesome for clinicians, effective treatment has not yet been established. Based on clinical...

Cite
Tadokoro S, Nonomura N, Kanahara N, et al. Reduction of Severity of Recurrent Psychotic Episode by Sustained Treatment with Aripiprazole in a Schizophrenic Patient with Dopamine Supersensitivity: A Case Report. Clin Psychopharmacol Neurosci. 2017;15(1):79-81doi: 10.9758/cpn.2017.15.1.79.
Tadokoro, S., Nonomura, N., Kanahara, N., Hashimoto, K., & Iyo, M. (2017). Reduction of Severity of Recurrent Psychotic Episode by Sustained Treatment with Aripiprazole in a Schizophrenic Patient with Dopamine Supersensitivity: A Case Report. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 15(1), 79-81. https://doi.org/10.9758/cpn.2017.15.1.79
Tadokoro, Shigenori, et al. "Reduction of Severity of Recurrent Psychotic Episode by Sustained Treatment with Aripiprazole in a Schizophrenic Patient with Dopamine Supersensitivity: A Case Report." Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology vol. 15,1 (2017): 79-81. doi: https://doi.org/10.9758/cpn.2017.15.1.79
Tadokoro S, Nonomura N, Kanahara N, Hashimoto K, Iyo M. Reduction of Severity of Recurrent Psychotic Episode by Sustained Treatment with Aripiprazole in a Schizophrenic Patient with Dopamine Supersensitivity: A Case Report. Clin Psychopharmacol Neurosci. 2017 Feb 28;15(1):79-81. doi: 10.9758/cpn.2017.15.1.79. PMID: 28138118; PMCID: PMC5290712.
Copy Download .nbib Format: NLM
Carisoprodol withdrawal syndrome resembling neuroleptic malignant syndrome: Diagnostic dilemma.

Journal of anaesthesiology, clinical pharmacology

Paul G, Parshotam GL, Garg R.
PMID: 27625493
J Anaesthesiol Clin Pharmacol. 2016 Jul-Sep;32(3):387-8. doi: 10.4103/0970-9185.173346.

Soma (Carisoprodol) is N-isopropyl-2 methyl-2-propyl-1,3-propanediol dicarbamate; a commonly prescribed, centrally acting skeletal muscle relaxant. Neuroleptic malignant syndrome (NMS) is a potentially life-threatening adverse effect of antipsychotic agents. Although diagnostic criteria for NMS have been established, it should be recognized...

Cite
Paul G, Parshotam GL, Garg R. Carisoprodol withdrawal syndrome resembling neuroleptic malignant syndrome: Diagnostic dilemma. J Anaesthesiol Clin Pharmacol. 2016;32(3):387-8doi: 10.4103/0970-9185.173346.
Paul, G., Parshotam, G. L., & Garg, R. (2016). Carisoprodol withdrawal syndrome resembling neuroleptic malignant syndrome: Diagnostic dilemma. Journal of anaesthesiology, clinical pharmacology, 32(3), 387-8. https://doi.org/10.4103/0970-9185.173346
Paul, Gunchan, et al. "Carisoprodol withdrawal syndrome resembling neuroleptic malignant syndrome: Diagnostic dilemma." Journal of anaesthesiology, clinical pharmacology vol. 32,3 (2016): 387-8. doi: https://doi.org/10.4103/0970-9185.173346
Paul G, Parshotam GL, Garg R. Carisoprodol withdrawal syndrome resembling neuroleptic malignant syndrome: Diagnostic dilemma. J Anaesthesiol Clin Pharmacol. 2016 Jul-Sep;32(3):387-8. doi: 10.4103/0970-9185.173346. PMID: 27625493; PMCID: PMC5009851.
Copy Download .nbib Format: NLM
Adjunctive Lurasidone Suppresses Food Intake and Weight Gain Associated with Olanzapine Administration in Rats.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology

Reynolds GP, Dalton CF, Watrimez W, Jackson J, Harte MK.
PMID: 30905132
Clin Psychopharmacol Neurosci. 2019 May 31;17(2):314-317. doi: 10.9758/cpn.2019.17.2.314.

OBJECTIVE: : Lurasidone is an antipsychotic drug that shows a relative lack of weight gain common to many antipsychotics. Aripiprazole and ziprasidone also show little weight gain and can reduce olanzapine-induced food intake and weight gain in animals, paralleling...

Cite
Reynolds GP, Dalton CF, Watrimez W, et al. Adjunctive Lurasidone Suppresses Food Intake and Weight Gain Associated with Olanzapine Administration in Rats. Clin Psychopharmacol Neurosci. 2019;17(2):314-317doi: 10.9758/cpn.2019.17.2.314.
Reynolds, G. P., Dalton, C. F., Watrimez, W., Jackson, J., & Harte, M. K. (2019). Adjunctive Lurasidone Suppresses Food Intake and Weight Gain Associated with Olanzapine Administration in Rats. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 17(2), 314-317. https://doi.org/10.9758/cpn.2019.17.2.314
Reynolds, Gavin P, et al. "Adjunctive Lurasidone Suppresses Food Intake and Weight Gain Associated with Olanzapine Administration in Rats." Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology vol. 17,2 (2019): 314-317. doi: https://doi.org/10.9758/cpn.2019.17.2.314
Reynolds GP, Dalton CF, Watrimez W, Jackson J, Harte MK. Adjunctive Lurasidone Suppresses Food Intake and Weight Gain Associated with Olanzapine Administration in Rats. Clin Psychopharmacol Neurosci. 2019 May 31;17(2):314-317. doi: 10.9758/cpn.2019.17.2.314. PMID: 30905132; PMCID: PMC6478088.
Copy Download .nbib Format: NLM
Neuroleptic malignant syndrome.

Journal of family medicine and primary care

Rajamani B, Kumar Y, Rahman SM.
PMID: 27453870
J Family Med Prim Care. 2016 Jan-Mar;5(1):178-80. doi: 10.4103/2249-4863.184660.

Neuroleptic malignant syndrome (NMS) is a life-threatening emergency that is often seen as a complication of antipsychotic agents. It is characterized by a tetrad of motor, behavioral, autonomic, and laboratory abnormalities. We report a case of a 34-year-old man...

Cite
Rajamani B, Kumar Y, Rahman SM. Neuroleptic malignant syndrome. J Family Med Prim Care. 2016;5(1):178-80doi: 10.4103/2249-4863.184660.
Rajamani, B., Kumar, Y., & Rahman, S. M. (2016). Neuroleptic malignant syndrome. Journal of family medicine and primary care, 5(1), 178-80. https://doi.org/10.4103/2249-4863.184660
Rajamani, Bino, et al. "Neuroleptic malignant syndrome." Journal of family medicine and primary care vol. 5,1 (2016): 178-80. doi: https://doi.org/10.4103/2249-4863.184660
Rajamani B, Kumar Y, Rahman SM. Neuroleptic malignant syndrome. J Family Med Prim Care. 2016 Jan-Mar;5(1):178-80. doi: 10.4103/2249-4863.184660. PMID: 27453870; PMCID: PMC4943133.
Copy Download .nbib Format: NLM
Effectiveness in Switching from Antipsychotic Polypharmacy to Monotherapy in Patients with Schizophrenia: A Case Series.

Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology

Kamei H, Yamada H, Hatano M, Hanya M, Yamada S, Iwata N.
PMID: 31958917
Clin Psychopharmacol Neurosci. 2020 Feb 29;18(1):159-163. doi: 10.9758/cpn.2020.18.1.159.

In Japan, drug therapy for schizophrenia is characterized by high-dose antipsychotic polypharmacy, which is an uncommon approach internationally. In this study, we reduced the number of antipsychotic agents in 5 patients using the Safety Correction of High-dose Antipsychotic Polypharmacy...

Cite
Kamei H, Yamada H, Hatano M, et al. Effectiveness in Switching from Antipsychotic Polypharmacy to Monotherapy in Patients with Schizophrenia: A Case Series. Clin Psychopharmacol Neurosci. 2020;18(1):159-163doi: 10.9758/cpn.2020.18.1.159.
Kamei, H., Yamada, H., Hatano, M., Hanya, M., Yamada, S., & Iwata, N. (2020). Effectiveness in Switching from Antipsychotic Polypharmacy to Monotherapy in Patients with Schizophrenia: A Case Series. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, 18(1), 159-163. https://doi.org/10.9758/cpn.2020.18.1.159
Kamei, Hiroyuki, et al. "Effectiveness in Switching from Antipsychotic Polypharmacy to Monotherapy in Patients with Schizophrenia: A Case Series." Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology vol. 18,1 (2020): 159-163. doi: https://doi.org/10.9758/cpn.2020.18.1.159
Kamei H, Yamada H, Hatano M, Hanya M, Yamada S, Iwata N. Effectiveness in Switching from Antipsychotic Polypharmacy to Monotherapy in Patients with Schizophrenia: A Case Series. Clin Psychopharmacol Neurosci. 2020 Feb 29;18(1):159-163. doi: 10.9758/cpn.2020.18.1.159. PMID: 31958917; PMCID: PMC7006980.
Copy Download .nbib Format: NLM
Parameters of Calcium Metabolism Fluctuated during Initiation or Changing of Antipsychotic Drugs.

Psychiatry investigation

Milovanovic DR, Stanojevic Pirkovic M, Zivancevic Simonovic S, Matovic M, Djukic Dejanovic S, Jankovic SM, Ravanic D, Petronijevic M, Ignjatovic Ristic D, Mladenovic V, Jovanovic M, Nikolic Labovic S, Pajovic M, Djokovic D, Petrovic D, Janjic V.
PMID: 26766951
Psychiatry Investig. 2016 Jan;13(1):89-101. doi: 10.4306/pi.2016.13.1.89. Epub 2015 Oct 14.

OBJECTIVE: Serum parameters of calcium homeostasis were measured based on previously published evidence linking osteoporotic fractures and/or bone/mineral loss with antipsychotics.METHODS: Prospective, four-week, time-series trial was conducted and study population consisted of patients of both genders, aged 35-85 years,...

Cite
Milovanovic DR, Stanojevic Pirkovic M, Zivancevic Simonovic S, et al. Parameters of Calcium Metabolism Fluctuated during Initiation or Changing of Antipsychotic Drugs. Psychiatry Investig. 2015;13(1):89-101doi: 10.4306/pi.2016.13.1.89.
Milovanovic, D. R., Stanojevic Pirkovic, M., Zivancevic Simonovic, S., Matovic, M., Djukic Dejanovic, S., Jankovic, S. M., Ravanic, D., Petronijevic, M., Ignjatovic Ristic, D., Mladenovic, V., Jovanovic, M., Nikolic Labovic, S., Pajovic, M., Djokovic, D., Petrovic, D., & Janjic, V. (2016). Parameters of Calcium Metabolism Fluctuated during Initiation or Changing of Antipsychotic Drugs. Psychiatry investigation, 13(1), 89-101. https://doi.org/10.4306/pi.2016.13.1.89
Milovanovic, Dragan R, et al. "Parameters of Calcium Metabolism Fluctuated during Initiation or Changing of Antipsychotic Drugs." Psychiatry investigation vol. 13,1 (2016): 89-101. doi: https://doi.org/10.4306/pi.2016.13.1.89
Milovanovic DR, Stanojevic Pirkovic M, Zivancevic Simonovic S, Matovic M, Djukic Dejanovic S, Jankovic SM, Ravanic D, Petronijevic M, Ignjatovic Ristic D, Mladenovic V, Jovanovic M, Nikolic Labovic S, Pajovic M, Djokovic D, Petrovic D, Janjic V. Parameters of Calcium Metabolism Fluctuated during Initiation or Changing of Antipsychotic Drugs. Psychiatry Investig. 2016 Jan;13(1):89-101. doi: 10.4306/pi.2016.13.1.89. Epub 2015 Oct 14. PMID: 26766951; PMCID: PMC4701691.
Copy Download .nbib Format: NLM
Pharmacologic Management of Agitation and Aggression in a Pediatric Emergency Department - A Retrospective Cohort Study.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG

Kendrick JG, Goldman RD, Carr RR.
PMID: 30697130
J Pediatr Pharmacol Ther. 2018 Nov-Dec;23(6):455-459. doi: 10.5863/1551-6776-23.6.455.

BACKGROUND: Benzodiazepine and antipsychotic use for acute management of agitation and aggression in the pediatric emergency department (ED) setting has not been well described.OBJECTIVES: To describe medication utilization in the management of agitation and aggression in a pediatric ED...

Cite
Kendrick JG, Goldman RD, Carr RR. Pharmacologic Management of Agitation and Aggression in a Pediatric Emergency Department - A Retrospective Cohort Study. J Pediatr Pharmacol Ther. 2018;23(6):455-459doi: 10.5863/1551-6776-23.6.455.
Kendrick, J. G., Goldman, R. D., & Carr, R. R. (2018). Pharmacologic Management of Agitation and Aggression in a Pediatric Emergency Department - A Retrospective Cohort Study. The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 23(6), 455-459. https://doi.org/10.5863/1551-6776-23.6.455
Kendrick, Jennifer G, et al. "Pharmacologic Management of Agitation and Aggression in a Pediatric Emergency Department - A Retrospective Cohort Study." The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG vol. 23,6 (2018): 455-459. doi: https://doi.org/10.5863/1551-6776-23.6.455
Kendrick JG, Goldman RD, Carr RR. Pharmacologic Management of Agitation and Aggression in a Pediatric Emergency Department - A Retrospective Cohort Study. J Pediatr Pharmacol Ther. 2018 Nov-Dec;23(6):455-459. doi: 10.5863/1551-6776-23.6.455. PMID: 30697130; PMCID: PMC6336173.
Copy Download .nbib Format: NLM
Bone mineral density and general health of long-term residential psychiatric inpatients.

Irish journal of psychological medicine

Hallahan B, Lyons D, Doyle P.
PMID: 30282216
Ir J Psychol Med. 2008 Sep;25(3):95-99. doi: 10.1017/S0790966700011095.

OBJECTIVE: The aim of this study was to determine the rates of osteopenia and osteoporosis and other general health problems in a long-stay male psychiatric unit.METHOD: All 15 patients underwent a semi-structured clinical interview and a full physical examination...

Cite
Hallahan B, Lyons D, Doyle P. Bone mineral density and general health of long-term residential psychiatric inpatients. Ir J Psychol Med. 2008;25(3):95-99doi: 10.1017/S0790966700011095.
Hallahan, B., Lyons, D., & Doyle, P. (2008). Bone mineral density and general health of long-term residential psychiatric inpatients. Irish journal of psychological medicine, 25(3), 95-99. https://doi.org/10.1017/S0790966700011095
Hallahan, Brian, et al. "Bone mineral density and general health of long-term residential psychiatric inpatients." Irish journal of psychological medicine vol. 25,3 (2008): 95-99. doi: https://doi.org/10.1017/S0790966700011095
Hallahan B, Lyons D, Doyle P. Bone mineral density and general health of long-term residential psychiatric inpatients. Ir J Psychol Med. 2008 Sep;25(3):95-99. doi: 10.1017/S0790966700011095. PMID: 30282216.
Copy Download .nbib Format: NLM
Cannabidiol Cigarettes as Adjunctive Treatment for Psychotic Disorders - A Randomized, Open-Label Pilot-Study.

Frontiers in psychiatry

Köck P, Lang E, Trulley VN, Dechent F, Mercer-Chalmers-Bender K, Frei P, Huber C, Borgwardt S.
PMID: 34803760
Front Psychiatry. 2021 Nov 04;12:736822. doi: 10.3389/fpsyt.2021.736822. eCollection 2021.

No abstract available.

Cite
Köck P, Lang E, Trulley VN, et al. Cannabidiol Cigarettes as Adjunctive Treatment for Psychotic Disorders - A Randomized, Open-Label Pilot-Study. Front Psychiatry. 2021;12:736822doi: 10.3389/fpsyt.2021.736822.
Köck, P., Lang, E., Trulley, V. N., Dechent, F., Mercer-Chalmers-Bender, K., Frei, P., Huber, C., & Borgwardt, S. (2021). Cannabidiol Cigarettes as Adjunctive Treatment for Psychotic Disorders - A Randomized, Open-Label Pilot-Study. Frontiers in psychiatry, 12736822. https://doi.org/10.3389/fpsyt.2021.736822
Köck, Patrick, et al. "Cannabidiol Cigarettes as Adjunctive Treatment for Psychotic Disorders - A Randomized, Open-Label Pilot-Study." Frontiers in psychiatry vol. 12 (2021): 736822. doi: https://doi.org/10.3389/fpsyt.2021.736822
Köck P, Lang E, Trulley VN, Dechent F, Mercer-Chalmers-Bender K, Frei P, Huber C, Borgwardt S. Cannabidiol Cigarettes as Adjunctive Treatment for Psychotic Disorders - A Randomized, Open-Label Pilot-Study. Front Psychiatry. 2021 Nov 04;12:736822. doi: 10.3389/fpsyt.2021.736822. eCollection 2021. PMID: 34803760; PMCID: PMC8599279.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 356 entries